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Warfarin-induced skin necrosis in HIV-1-infected patients 
with tuberculosis and venous thrombosis
F Bhaijee, H Wainwright, G Meintjes, R J Wilkinson, G Todd, E de Vries, D J Pepper
Warfarin-induced skin necrosis (WISN) is a rare complication 
of warfarin therapy, with an estimated prevalence of 0.01 - 
0.1% in individuals receiving warfarin.1,2 WISN is associated 
with high morbidity, often necessitating aggressive surgical 
intervention, and may be fatal in the absence of early accurate 
diagnosis and treatment. Originally described in 1943, WISN 
was first associated with oral anticoagulants in 1954.3 By 
2000, only 300 cases had been reported internationally.4 
Most cases occur in patients receiving treatment for venous 
thrombo-embolism (VTE); 25% of WISN occurs in patients 
with cardiac indications for therapy (e.g. atrial fibrillation, 
valve replacement) or cerebrovascular insufficiency.2 To date, 
published reports do not associate WISN with HIV-1 infection 
or tuberculosis (TB). We describe 6 cases of WISN with poor 
outcome occurring in HIV-1-infected patients receiving 
treatment for TB. 
Methods
Setting
We retrospectively reviewed 6 cases of WISN seen at G F Jooste 
Hospital (Cape Town, South Africa) from April 2005 through 
July 2008. G F Jooste Hospital is a 200-bed adult (>15 years) 
public hospital that receives referrals from primary care clinics 
serving a catchment population of 1.3 million high-density, 
low-income people. We have previously described national 
guidelines for antituberculosis treatment and antiretroviral 
therapy in South Africa.5,6 The Research Ethics Committee 
of the University of Cape Town approved the study (REF: 
182/2009).
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Background. At the turn of the century, only 300 cases of 
warfarin-induced skin necrosis (WISN) had been reported. 
WISN is a rare but potentially fatal complication of warfarin 
therapy. There are no published reports of WISN occurring in 
patients with HIV-1 infection or tuberculosis (TB).
Methods. We retrospectively reviewed cases of WISN 
presenting from April 2005 to July 2008 at a referral hospital 
in Cape Town, South Africa.
Results. Six cases of WISN occurred in 973 patients receiving 
warfarin therapy for venous thrombosis (0.62%, 95% CI 
0.25 - 1.37%). All 6 cases occurred in HIV-1-infected women 
(median age 30 years, range 27 - 42) with microbiologically 
confirmed TB and venous thrombosis. All were profoundly 
immunosuppressed (median CD4+ count at TB diagnosis 
49 cells/µl, interquartile range 23 - 170). Of the 3 patients 
receiving combination antiretroviral therapy, 2 had TB-IRIS 
(immune reconstitution inflammatory syndrome). The median 
interval from initiation of antituberculosis treatment to 
venous thrombosis was 37 days (range 0 - 150). The median 
duration of parallel heparin and warfarin therapy was 2 
days (range 1 - 6). WISN manifested 6 days (range 4 - 8) after 
initiation of warfarin therapy. The international normalised 
ratio (INR) at WISN onset was supra-therapeutic, median 
5.6 (range 3.8 - 6.6). Sites of WISN included breasts, buttocks 
and thighs. Four of 6 WISN sites were secondarily infected 
with drug-resistant nosocomial bacteria (methicillin-resistant 
Staphylococcus aureus (MRSA), Acinetobacter, extended-
spectrum β-lactamase (ESBL)-producing Escherichia coli and 
Klebsiella pneumoniae) 17 - 37 days after WISN onset. In 4 
patients, the median interval from WISN onset to death was 
43 days (range 25 - 45). One of the 2 patients who survived 
underwent bilateral mastectomies and extensive skin grafting 
at a specialist centre. 
Conclusion. This is one of the largest case series of WISN. 
We report a novel clinical entity: WISN in HIV-1 infected 
patients with TB and venous thrombosis. The occurrence 
of 6 WISN cases in a 40-month period may be attributed to 
(i) hypercoagulability, secondary to HIV-1 and TB; (ii) short 
concurrent heparin and warfarin therapy; and (iii) high 
loading doses of warfarin. Active prevention and appropriate 
management of WISN are likely to improve the dire 
morbidity and mortality of this unusual condition. 
S Afr Med J 2010; 100: 372-377.
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Definitions
We defined venous thrombosis as either visualisation of a non-
compressible thrombus with Doppler ultrasound (popliteal 
or femoral venous thrombosis) or a venous filling defect with 
radio-contrast during computed tomography (CT) (inferior 
vena cava or superior sagittal sinus thrombosis). A radiologist 
performed sonography and interpreted the CT findings. WISN 
was defined as a characteristic drug eruption on the skin, 
occurring shortly after starting warfarin therapy for a venous 
thrombosis and progressing to skin and subcutaneous tissue 
loss. We defined the following: microbiologically confirmed 
TB as Mycobacterium tuberculosis cultured or acid-fast bacilli 
(AFB) seen in sputum or a lymph node aspirate; TB-IRIS 
(immune reconstitution inflammatory syndrome) using the 
consensus clinical case definition of paradoxical TB-IRIS for 
resource-limited settings;7 extended-spectrum beta-lactamase 
(ESBL)-producing bacteria as bacteria having clavulanate-
inhibited transferable enzymes able to hydrolyse third- and 
fourth-generation cephalosporins as tested by the disc diffusion 
(fishtail) method; and methicillin-resistant Staphylococcus 
aureus (MRSA) as having an oxacillin minimum inhibitory 
concentration of >4 mg/l.
Materials 
We obtained clinical information from hospital notes, 
laboratory reports and communication with attending 
physicians. The following data were reviewed: patient 
demographics, HIV-1 status, CD4+ counts (nadir and post-ART 
where available), TB episode (microbiological confirmation, 
drug susceptibility testing), site of venous thrombosis, 
anticoagulation therapy, site of WISN, international normalised 
ratio (INR) at WISN onset, antibiotic treatment, and outcome 
(e.g. death, surgical intervention). All patients admitted to G F 
Jooste Hospital from 2005 through 2008 were managed using a 
standardised venous thrombosis protocol. Following diagnosis 
of venous thrombosis, low-molecular-weight (LMW) heparin 
(enoxaparin 1 mg/kg twice daily by deep subcutaneous 
injection) was prescribed for a maximum of 5 days. Warfarin 
was started 2 days after heparin initiation to minimise the risk 
of warfarin-induced skin necrosis. If the patient was receiving 
TB treatment for 10 days or longer, the loading dose of 
warfarin was adjusted from 5 mg to 10 mg. 
Results
Baseline characteristics
Nine hundred and seventy-three patients were diagnosed 
with venous thromboses and received warfarin therapy at 
G F Jooste Hospital over the 40-month study period. WISN 
occurred in 6 HIV-1-infected women receiving treatment for 
microbiologically confirmed TB (Table I). The prevalence of 
WISN in our study population was 0.62% (6/973) (95% CI 
0.25 - 1.37%). The median age was 33 years (range 27 - 42). 
The median CD4+ count at TB diagnosis was 49 cells/µl 
(interquartile range 23 - 170). Three patients received ART 
(regimens specified in Table I). Two patients (cases 2 and 
3) were diagnosed with TB-IRIS. The median interval from 
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initiation of antituberculosis therapy to venous thrombosis 
was 37 days (range 0 - 150). Venous thrombosis sites included 
popliteal and femoral veins, the inferior vena cava, and the 
superior sagittal sinus. Only patient 3 was an inpatient at 
the time of venous thrombosis (and received LMW heparin 
prophylaxis); the remaining patients were admitted to hospital 
as a result of venous thrombosis. No patient had a personal or 
family history of previous venous thrombosis. 
Clinical features at WISN and outcomes 
The warfarin loading dose was 5 mg or 10 mg (Table II). The 
median duration of parallel heparin and warfarin therapy was 
2 days (range 1 - 6) and the median interval from initiation 
of warfarin therapy to WISN was 6 days (range 4 - 8). The 
INR at WISN onset was supra-therapeutic, median 5.6 (range 
3.8 - 6.6). Activated partial thromboplastin times (aPTT) were 
not measured. Sites of WISN included the breasts, buttocks 
and thighs (Fig. 1). Skin biopsy was performed in 1 patient 
(Fig. 1). After WISN diagnosis, warfarin was stopped and 
LMW heparin was used to manage anticoagulation. Wound 
cultures from infected WISN sites produced the following 
drug-resistant nosocomial organisms: Escherichia coli (ESBL), 
Klebsiella pneumoniae (ESBL), S. aureus (MRSA), Acinetobacter 
baumannii and Serratia marcescens. Antimicrobial sensitivities of 
each organism are listed in Table II.
Four patients died, and no autopsies were performed. All 4 
patients were profoundly immunosuppressed at TB diagnosis. 
The median interval from WISN onset to death was 43 days 
(range 25 - 45). The two surviving patients’ CD4+ counts at 
TB diagnosis exceeded 200 cells/µl. Patient 1 was referred to 
a specialist centre for aggressive surgical management (Fig. 1, 
D - F). Patient 6 recovered with appropriate wound care and 
prophylactic broad-spectrum intravenous antibiotics (a third-
generation cephalosporin). 
Discussion
This is one of the largest case series of WISN. We report a novel 
clinical entity: WISN occurring in HIV-1-infected patients with 
TB and venous thrombosis. 
All 6 patients were chronically ill women of reproductive 
age with venous thromboses. WISN typically occurs in obese, 
perimenopausal women who are receiving anticoagulant 
therapy for a deep-vein thrombosis or pulmonary embolism.2 
Women are affected more frequently than men (4:1)2 – the 
reason for this predilection is unclear. In women, the breast is 
most commonly affected, followed by the buttocks and thighs;8 
our patients were similarly affected. It is postulated that local 
tissue factors contribute to the development of WISN at these 
sites, and that such factors include trauma and variation in 
local temperature and perfusion.9,10 
About 90% of affected patients develop symptoms between 
the 3rd and 6th day of warfarin therapy,2,4,11 which is similar 
to our experience. The clinical presentation of WISN is 
characteristic (Fig. 1, A - C); all our patients demonstrated these 
clinical features. Widespread disease may result in deep tissue 
necrosis, secondary infection and multi-organ failure.2 
Mortality within 3 months of WISN onset is substantial 
(15%), even with appropriate treatment.2 Four of our 6 patients 
died within 45 days of onset. All deaths were probably due 
to a sepsis syndrome complicating wound infection. All 
wound cultures were taken from infected wounds. These were 
not surveillance cultures. Prior rifampicin, trimethoprim-
sulfamethoxazole and cephalosporin use in our patients may 
have favoured the selection of highly antibiotic-resistant 
organisms. In South Africa, more than 50% of S. aureus 
isolates from public hospitals are resistant to rifampicin and/
or trimethoprim sulfamethoxazole.12 Failure of effective 
infection control measures, lack of appropriate antimicrobial 
chemotherapy,6 delayed referral to a specialist centre for 
surgical debridement, and profound immunosuppression at TB 
diagnosis probably contributed to the 4 deaths. In contrast, the 
superior immune function at TB diagnosis of patients 1 and 6 
may account for their survival. Pulmonary emboli may have 
also complicated warfarin cessation and contributed to death. 
We were unable to determine the exact cause of death, as the 
patients’ relatives declined consent to perform autopsies. It is 
important to note that despite prompt referral to a specialist 
centre, patient 1 had considerable morbidity including bilateral 
mastectomies, an impaired gait due to a contracture of her left 
thigh, and the associated psychosocial stigma. 
Classic histological features of WISN include full-thickness 
epidermal necrosis and  thrombosed vessels in the dermis. 
While the underlying pathophysiological mechanisms remain 
unclear, it is postulated that WISN results from an imbalance 
between intrinsic pro- and anticoagulant factors during the 
first few days of warfarin therapy.2,11 Warfarin is a vitamin K 
antagonist and reduces serum levels of vitamin K-dependent 
factors, which include factors II, VII, IX and X, protein C and 
protein S. Serum levels of factor VII (a procoagulant factor), 
and proteins C and S (anticoagulant factors) decline more 
rapidly than serum levels of factors II, IX and X (procoagulant 
factors) on warfarin therapy.2,11 This results in an initial 
hypercoagulable state, which, especially in the presence of 
additional risk factors such as protein C and/or S deficiency, 
may predispose to WISN.4 The INR is factor VII-dependent, 
so patients will have a raised INR, but a relative protein C 
deficiency will nonetheless result in a hypercoagulable state.13 
Screening for these conditions before warfarin initiation is not 
recommended, however, as they lack the necessary sensitivity 
and specificity to accurately predict the risk of developing 
WISN.2,4 Owing to the retrospective nature of our study, serum 
levels of protein C, protein S and antithrombin III were not 
measured. The lack of genetic testing and coagulation work-up 
is a limitation of our study. 
The prevalence of WISN in our study population is 0.62% 
(6/973), which is six times higher than that reported in HIV-
uninfected patients.1,2 The occurrence of 6 WISN cases in a 
40-month period at one centre is unusual. It may be a result 
of the short duration of parallel heparin and warfarin therapy 
(median 2 days) observed in our patients. Parallel heparin and 
warfarin therapy is postulated to prevent the development of 
WISN, and should be continued until the vitamin K-dependent 
clotting factors have been consumed (72 - 96 hours).2,4,8,11 
In our patients, premature cessation of heparin during the 
initial hypercoagulable period of warfarin therapy may have 
exacerbated an underlying hypercoagulable disorder (such as 
a protein C or S deficiency) and culminated in WISN. In our 
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setting, we routinely prescribe a loading dose of 5 or 10 mg of 
warfarin in TB patients with venous thromboses, as rifampicin 
induces the rate of warfarin clearance by cytochrome p450 
(CYP) 2C9.14 This dose of warfarin with a short window of 
parallel heparin and warfarin therapy may have contributed to 
the high prevalence of WISN (0.62%).
HIV infection is a widely acknowledged risk factor for 
VTE.15-17 Some reports cite a tenfold increase in the incidence of 
deep-vein thrombosis (DVT) in HIV/AIDS as opposed to the 
general population.15 The following independent risk factors 
have been identified for VTE in HIV-positive patients: low CD4 
count, high viral load, advanced stage of immunocompromise, 
opportunistic infections, AIDS-related neoplasms, HIV-
associated auto-immune disorders (e.g. auto-immune 
haemolytic anaemia), hospitalisation in the past 3 months, and 
central venous catheter use in the past 3 months.16-18 Exposure 
to antiretroviral therapy (ART) has not been associated 
with VTE.16,17 HIV-positive patients are also more likely to 
demonstrate multiple acquired and persistent thrombophilic 
abnormalities; the frequency of these abnormalities increases 
with progression to AIDS, and their presence may contribute 
to the high prevalence of venous and arterial thrombosis 
in patients with HIV infection.19 These abnormalities 
include antiphospholipid antibodies, lupus anticoagulant, 
anticardiolipin antibodies, increased von Willebrand factor, 
increased d-dimers, and deficiencies of protein C, protein S, 
antithrombin and heparin cofactor II.20 The acquired protein 
S and protein C deficiencies seen in acutely ill patients may 
be reversible following treatment for opportunistic infections 
and/or ART.18 
M. tuberculosis infection may present clinically as DVT; 
2 of our patients (patients 1 and 4) were diagnosed with 
TB and DVT simultaneously. DVT usually occurs shortly 
after initiating antituberculosis therapy (about 2 weeks).21 
Rifampicin-based regimens have a fivefold increased risk of 
DVT (relative risk = 5), so DVT prevention is recommended in 
patients on rifampicin.21 DVT is also associated with advanced 
HIV infection and PTB. The following thrombogenic factors 
probably contribute to this association: acquired protein C and 
protein S deficiencies, elevated plasma fibrinogen, impaired 
fibrinolysis, depressed ATIII, reactive thrombocytosis, increased 
platelet aggregation, and antiphospholipid antibodies.22 These 
parameters may improve with antituberculosis treatment.22
Fig. 1, A - C: Left thigh of patient 6 showing typical macroscopic features of warfarin-induced skin necrosis. A painful, well-localised purplish lesion with a 
poorly demarcated erythematous flush9 developed 6 days after commencing warfarin therapy (A). Oedema formed in the dermis and subcutaneous tissues, 
which elevated and further demarcated the lesions from unaffected skin (B). Petechiae and haemorrhagic bullae were also observed; such bullae signified irre-
versible damage and ensuing full-thickness skin necrosis.3,4,9 Sloughing of the eschar revealed deep defects that extended into the subcutaneous tissue (C). D - 
F: WISN in an HIV-1-infected woman with tuberculosis and venous thrombosis (patient 1). A 42-year-old HIV-infected woman was admitted to hospital in 
June 2008. She was compliant with antiretroviral treatment (ART), and her CD4 count was 396 cells/µl. Drug-sensitive Mycobacterium tuberculosis was 
cultured from her sputa. Ultrasound examination confirmed a left popliteal thrombosis. Six days after starting warfarin therapy she developed skin lesions on 
her breasts and left thigh, consistent with WISN (D). Sixteen days after WISN onset, a punch biopsy of her left thigh was performed. Histological examina-
tion showed full-thickness epidermal necrosis with numerous thrombosed vessels in the superficial dermis (E, arrowed), consistent with WISN. She received 
antibiotics for wound infection according to microbial sensitivities. Forty-four days after WISN onset, plastic surgeons performed a bilateral mastectomy and 
extensive tissue excision from the left thigh. Split-thickness skin grafts were used to cover the defects. Microscopy of tissue excised from the left thigh showed 
extensive necrosis of subcutaneous fat, numerous foreign body-type giant cells and focal suppuration (F, arrowed). There were fresh thrombi in vessels, and 
some vessels showed recanalisation. No organisms were seen on Brown and Brenn (modified Gram stain) or Ziehl-Neelsen stains. Ten months after WISN, 
she has an impaired gait due to a contracture of her left thigh.
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It is not known whether IRIS predisposes to venous 
thrombosis. A single case is reported of IRIS manifesting as 
disseminated TB, myelopathy, encephalopathy and DVT;23 
with appropriate treatment, IRIS resolved and no adverse 
drug effects occurred. We report the first 2 cases of TB-IRIS 
and WISN occurring simultaneously. The 2 patients diagnosed 
with TB-IRIS were profoundly immunosuppressed, had a short 
duration from starting antituberculosis treatment to initiation 
of ART, and presented with recurrence of TB symptoms soon 
after initiating ART.7
Active prevention and appropriate management of venous 
thromboses are likely to alleviate the dire morbidity and 
mortality associated with WISN. Prophylactic heparinisation 
of acutely ill hospital patients with HIV-1 infection and/
or TB will reduce the incidence of venous thrombosis. In 
patients with venous thrombosis, parallel heparin therapy for 
at least the first 4 days of warfarinisation2,4,8,11 may limit the 
occurrence of WISN. WISN should be considered in all newly 
warfarinised patients with new skin lesions. Effective infection 
control measures and expedited referral to specialist centres for 
surgical review may reduce mortality.
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